Variations in systemic biomarkers of oxidative/nitrosative stress and DNA damage before and during the consequent two cycles of chemotherapy in breast cancer patients

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 10, 2010, Pages 1487-1495

  Atukeren, Pinar ^a   Yavuz, Berna ^a   Soydinc, Hilal Oguz ^b   Purisa, Sevim ^a   Camlica, Hakan ^b   Gumustas, M Koray ^a   Balcioglu, Ibrahim ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

8 hydroxydeoxyguanosine; breast cancer; chemotherapy; nitrosative stress; oxidative stress

Indexed keywords

3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FREE RADICAL; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; NITRATE; NITRITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; NITROSATIVE STRESS; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; REDOX STRESS; RISK FACTOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; BREAST NEOPLASMS; DEOXYGUANOSINE; DNA DAMAGE; FEMALE; HUMANS; MIDDLE AGED; NITRATES; NITRITES; NITROSATION; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROGNOSIS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR MARKERS, BIOLOGICAL; TYROSINE;

EID: 77958174287     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.249     Document Type: Article

References (49)

1. Hery C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol 2008;19:1009-18.
2. Ozmen V. Breast cancer in the World and Turkey. J Breast Health 2008;4:6-12.
3. Wolff MS, Weston A. Breast cancer risk and environmental exposures. Environ Health Persp 1997;105:891-6.
4. Lianidou ES, Melegos DN, Diamandis EP. BRCA1 tumor suppressor gene product shares immunoreactive epitopes with a protein present in seminal plasma. Clin Biochem 1997;30:425-32.
5. Kinnula VL, Crapo JD. Superoxide dismutases in malignant cells and human tumors. Free Radical Bio Med 2004;36:718-44.
6. Chirino YI, Chaverri-Pedraza J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009;61:223-42.
7. Otamiri T, Sjodahl R. Increased lipid peroxidation inmalignant tissues of patients with colorectal cancer. Cancer 1989;64:422-5.
8. Stevens RG, Nerishi K. Iron and oxidative damage in human cancer. In: Spartz L, Bloom AD, editors. Biological consequences of oxidative stress: implications for cardiovascular disease and carcinogenesis. New York: Oxford University Press, 1992:138-61.
9. Ames BN. Dietary carcinogens and anticarcinogens: oxygen radicals and degenerative diseases. Science 1983;221:1256-64.
10. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc T 2003;31:1441-4.
11. Ray G, Husain SA. Oxidants, antioxidants and carcinogenesis. Indian J Exp Biol 2002;40:1213-32.
12. Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues 2002;13:540-9.
13. Suzuki YJ, Forman HJ, Sevanian A. Oxidants as stimulators of signal transduction. Free Radical Bio Med 1997;22:269-85.
14. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998;19:711-21.
15. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003;140-141:105-12.
16. Monteiro HP. Signal transduction by protein tyrosine nitration: competition or cooperation with tyrosine phosphorylation dependent signal events? Free Radical Bio Med 2002;33:765-73.
17. Karihtala P, Soini Y, Auvinen P, Tammi R, Tammi M, Kosma VM. Hyaluronan in breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation. J Histochem Cytochem 2007;55:1191-8.
18. Jaremko M, Justenhoven C, Schroth W, Abraham BK, Fritz P, Vollmert C, et al. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil- based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics 2007;17:529-38.
19. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual, 6th ed. NY, Springer, 2002;223-40.
20. Buege JA, Aust SD. Microsomal lipid peroxidation. Method Enzymol 1978;12:302-10.
21. Kasapovic J, Pejic S, Todorovic A, Stojiljkovic V, Pajovic SB. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages. Cell Biochem Funct 2008;26:723-30.
22. Buico A, Cassino C, Ravera M, Betta PG, Osella D. Oxidative stress and total antioxidant capacity in human plasma. Redox Rep 2009;14:125-31.
23. Sener DE, Gonenc A, Akmer M, Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct 2007;25:377-82.
24. Polat MF, Taysi S, Gul M, Cikman O, Yilmaz I, Bakan E, et al. Oxidant/antioxidant status in blood of patients with malignant breast tumor and benign disease. Cell Biochem Funct 2002;20:327-31.
25. Kumaraguruparan R, Subapriya R, Kablimoorthy J, Nagini S. Antioxidant profile in the circulation of patients with fibroadenoma and adenocarcinoma of the breast. Clin Biochem 2002;35:275-9.
26. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, et al. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast Cancer Res Tr 2000;59:163-70.
27. Yeh C, Hou M, Tsai S, Lin S, Hsiao J, Huang J, et al. Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer. Clin Chim Acta 2005;361:104-11.
28. Portakal O, Ozkaya O, Erden IM, Bozan B, Kosan M, Sayek I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33:279-84.
29. Rajneesh CP, Manimaran A, Sasikala KR, Adaikappan P. Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Med J 2008;49:640-3.
30. Karihtala P, Winqvist R, Juhani E, Syvaoja JE, Kinnula VL, Soini Y. Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. Eur J Cancer 2006;42:2653-9.
31. Nowak D, Janczak M. Effect of chemotherapy on serum endproducts of lipid peroxidation in patients with small cell lung cancer: association with treatment results. Resp Med 2006;100:157-66.
32. Look MP, Musch E. Lipid peroxides in the polychemotherapy of cancer patients. Chemotherapy 1994;40:8-15.
33. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
34. Buzdar AU, Asmar L, Hortobagyi GN. Impact of patient characteristics on treatment outcome: anthracycline resistance. Eur J Cancer 1997;33: S3-6.
35. Pigram WJ, Fuller W, Hamilton LD. Stereochemistry of intercalation: interaction of daunorubicin with DNA. Nat New Biol 1972;235:17-9.
36. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL. Cleveage of DNA by mammalian topoisomerase II. J Biol Chem 1983;258:15365-70.
37. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin induced DNA damage mediated by mammalian topoisomerase II. Science 1984;226:466-8.
38. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979;76:954-7.
39. Beraldo H, Garnier-Suillerot A, Tosi L, Lavelle F. Iron (III) adriamycin and iron (III) daunorubicin complexes: physicochemical characteristics, interaction with DNA and antitumor activity. Biochemistry 1985;24:284-9.
40. Veril M. Anthracyclines in breast cancer: therapy and issues of toxicity. Breast 2001;2:8-15.
41. Erhola M, Kellokumpu-Lehtinen P, Metsa-Ketela T, Alanko K, Nieminen MM. Effects of anthracyclin-based chemotherapy on total plasma antioxidant capacity in small cell lung cancer patients. Free Radical Bio Med 1996;21:383-90.
42. Durken M, Herrnring C, Finckh B, Nagel S, Nielsen P, Fischer R, et al. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radical Bio Med 2000;28:887-94.
43. Kaya E, Keskin L, Aydogdu I, Kuku I, Bayraktar N, Erkut MA. Oxidant/antioxidant parameters and their relationship with chemotherapy in Hodgkin's lymphoma. J Int Med Res 2005;33:687-92.
44. Crohns M, Liippo K, Erhola M, Kankaanranta H, Moilanen E, Alho H, et al. Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer. Clin Biochem 2009;42:1236-45.
45. Khanzode SS, Muddeshwar MG, Khanzode SD, Dakhale GN. Antioxidant enzymes and lipid peroxidation in different stages of breast cancer. Free Radical Res 2004;38:81-5.
46. De Larco JE, Park CA, Dronava H, Furcht LT. Paradoxical roles for antioxidants in tumor prevention and eradication. Cancer Biol Ther 2010;9:362-70. Epub 2010 Mar. 8.
47. Pervin S, Chaudhuri G, Singh R. NO to breast: when, why and why not? Curr Pharm Design 2010;16:451-62.
48. Yasuoka H, Tsujimoto M, Yoshidome K, Nakahara M, Kodama R, Sanke T, et al. Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer 2008;8:340.
49. Sova H, Jukkola-Vuorinen A, Puistola U, Kauppila S, Karihtala P. 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br J Cancer 2010;102:1018-23. Epub 2010 Feb. 23.